172 related articles for article (PubMed ID: 3493065)
1. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL
J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
[TBL] [Abstract][Full Text] [Related]
5. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
Leonard JE; Johnson DE; Shawler DL; Dillman RO
Cancer Res; 1988 Sep; 48(17):4862-7. PubMed ID: 3261627
[TBL] [Abstract][Full Text] [Related]
7. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
9. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
10. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
11. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors.
Bjorn MJ; Groetsema G
Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979
[TBL] [Abstract][Full Text] [Related]
13. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hematopoietic progenitor colony growth by a monoclonal antibody against the transferrin receptor: comparison of unconjugated antibody with an immunotoxin containing recombinant ricin A chain.
Shannon KM; Ring DB; Houston LL; Schaffner V; Naylor J; Torkildson JC; Reid SA; Larrick J
Int J Cell Cloning; 1990 Sep; 8(5):368-76. PubMed ID: 2230286
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Calvete JA; Newell DR; Wright AF; Rose MS
Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
[TBL] [Abstract][Full Text] [Related]
16. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
17. Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
Laske DW; Muraszko KM; Oldfield EH; DeVroom HL; Sung C; Dedrick RL; Simon TR; Colandrea J; Copeland C; Katz D; Greenfield L; Groves ES; Houston LL; Youle RJ
Neurosurgery; 1997 Nov; 41(5):1039-49; discussion 1049-51. PubMed ID: 9361057
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
